Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
Study: A sterile syringe program already in place would have significantly reduced Scott County HIV incidence
Once outbreak was recognized, program put in place reduced number of ongoing transmissions, modeling shows In 2015, when 181 of rural Scott County, Indiana’s 24,000 residents […]
SYDNEY – When Merinda Sebayang was undergoing treatment for multidrug-resistant TB in Indonesia – a nation with the third highest tuberculosis burden in the world after […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
The following is guest post by Brittany Iskarpatyoti of the University of North Carolina at Chapel Hill When you drop a rock into a pool of […]